Disruption of hormonal balance and the potential development of cancer –⁠ the impact of endocrine disruptors

Czech version

Authors: K. Hilscherová; Z. Toušová; P. Mikušová; V. Janečková
Authors‘ workplace: RECETOX, PřF MU, Brno
Published in: Klin Onkol 2026; 39(Supplementum 1): 53-57
Category: Review
doi: https://doi.org/10.48095/ccko2026S53

Overview

Background: Endocrine-disrupting chemicals (EDCs) constitute a heterogeneous group of substances capable of interfering with hormonal regulation and thereby influencing the risk of initiation and progression of hormone-sensitive cancers. Their mechanisms of action include interactions with hormone receptors, modulation of hormone synthesis and metabolism, epigenetic alterations, and activation of specific signalling pathways. In recent years, the adverse outcome pathway (AOP) framework has gained prominence, as it enables linking molecular initiating events affected by EDCs to clinical outcomes, including carcinogenesis. An important role play thyroid hormones, which regulate cell proliferation, differentiation, and metabolism across tissues, and their deregulation by EDCs at multiple levels may influence the development of various cancer types. Objective: The aim of this article is to summarise current knowledge on the main mechanisms of endocrine disruption that can influence cancer initiation and progression, and to highlight the relevance of the AOP framework for predicting risks associated with EDC exposure. The objective also includes drawing attention to the major groups of EDCs whose exposure has been associated with an increased risk of hormone-sensitive cancers, as well as their sources. Conclusion: Endocrine-disrupting chemicals to which people are commonly exposed may represent an important factor affecting hormonal balance and the potential development of cancer. Understanding their molecular mechanisms of action is essential for risk assessment and the formulation of preventive strategies. The AOP framework offers a promising tool for linking mechanistic data with clinical consequences and for predicting the carcinogenic potential of these substances.

Keywords:

Hormones – endocrine disruptors – hazardous substances – adverse outcome pathways – hormone-sensitive cancers

Sources

1. Endocrine Society. Endocrine-disrupting chemicals. [online]. Available from: https: //www.endocrine.org/advocacy/position-statements/endocrine-disrupting-chemicals.

2. Gore AC, Chappell VA, Fenton SE et al. EDC-2: the endocrine society’s second scientific statement on endocrine-disrupting chemicals. Endocr Rev 2015; 36 (6): E1–E150. doi: 10.1210/er.2015-1010.

3. Portál epidemiologie novotvarů v ČR. [online]. Dostupné z: https: //www.svod.cz/.

4. International Agency for Research on Cancer. Cancer over time. [online]. Available from: https: //gco.iarc.fr/.

5. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC et al. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev 2009; 30 (4): 293–342. doi: 10.1210/er.2009-0002.

6. Parrish M, Kuperwasser C. Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer. Nat Rev Cancer 2025; 25 (11): 819–820. doi: 10.1038/s41568-025-00854-3.

7. Czaczkowska L, Jabłońska E, Ratajczak-Wrona W. Endocrine disruptors and breast cancer: a comprehensive review. Biomedicines 2025; 13 (11): 2774. doi: 10.3390/biomedicines13112774.

8. Biro FM, Huang B, Wasserman H et al. Pubertal growth, IGF-1, and windows of susceptibility: puberty and future breast cancer risk. J Adolesc Health 2021; 68 (3): 517–522. doi: 10.1016/j.jadohealth.2020.07.016.

9. Sewell F, Alexander-White C, Brescia S et al. New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption. Toxicol Res (Camb) 2024; 13 (2): tfae044. doi: 10.1093/toxres/tfae044.

10. Perkins EJ, Ashauer R, Burgoon L et al. Building and applying quantitative adverse outcome pathway models for chemical hazard and risk assessment. Environ Toxicol Chem 2019; 38 (9): 1850–1865. doi: 10.1002/etc.4505.

11. Lozano-Herrera SJ, García-Gutiérrez N, Hernández--Puga AG et al. Estrogenic endocrine disruptors and cancer: a narrative review. Endokrynol Pol 2025; 76 (3): 236–247. doi: 10.5603/ep.104430.

12. Miyakoshi T, Miyajima K, Takekoshi S et al. The influence of endocrine disrupting chemicals on the proliferation of eralpha knockdown-human breast cancer cell line MCF-7; new attempts by rnai technology. Acta Histochem Cytochem 2009; 42 (2): 23–28. doi: 10.1267/ahc.08036.

13. Zhou Z, Goodrich JM, Strakovsky RS. Mitochondrial epigenetics and environmental health: making a case for endocrine disrupting chemicals. Toxicol Sci 2020; 178 (1): 16–25. doi: 10.1093/toxsci/kfaa129.

14. AOP-Wiki. [online]. Available from: https: //aopwiki.org/.

15. Krashin E, Piekiełko-Witkowska A, Ellis M et al. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne) 2019; 10 : 59. doi: 10.3389/fendo.2019.00059.

16. Romitti M, Ceolin L, Siqueira DR et al. Signaling pathways in follicular cell-derived thyroid carcinomas (review). Int J Oncol 2013; 42 (1): 19–28. doi: 10.3892/ijo.2012.1681.

17. Pinto M, Soares P, Ribatti D. Thyroid hormone as a regulator of tumor induced angiogenesis. Cancer Letters 2011; 301 (2): 119–126. doi: 10.1016/j.canlet.2010.11.011.

18. Goemann IM, Romitti M, Meyer EL et al. Role of thyroid hormones in the neoplastic process: an overview. Endocr Relat Cancer 2017; 24 (11): R367–R385. doi: 10.1530/ERC-17-0192.

19. Franke TF. PI3K/AKT: getting it right matters. Oncogene 2008; 27 (50): 6473–6488. doi: 10.1038/onc.2008.313.

20. Miro C, Ambrosio R, De Stefano MA et al. The concerted action of type 2 and type 3 deiodinases regulates the cell cycle and survival of basal cell carcinoma cells. Thyroid 2017; 27 (4): 567–576. doi: 10.1089/thy.2016.0532.

21. Kumari P, Lungu-Mitea S, Novák J et al. Advancing in vitro assessment of iodide uptake inhibition: integrating a novel biotransformation pretreatment step. Arch Toxicol 2025; 99 (7): 2783–2799. doi: 10.1007/s00204-025-04034-y.

22. Spitzweg C, Nelson PJ, Wagner E et al. The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment. Endocr Relat Cancer 2021; 28 (10): T193–T213. doi: 10.1530/ERC-21-0177.

23. Modica C, Benevento E, Colao A. Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship. J Endocrinol Invest 2023; 46 (4): 667–677. doi: 10.1007/s40618-022-01983-4.

24. Program on Reproductive Health and the Environment. [online]. Available from: https: //prhe.ucsf.edu/communications?page=2.

25. Sajid M, Ilyas M. PTFE-coated non-stick cookware and toxicity concerns: a perspective. Environ Sci Pollut Res Int 2017; 24 (30): 23436–23440. doi: 10.1007/s11356-017-0095-y.

26. Park J, Lee H, Lee S et al. Interventions on reducing exposure to endocrine disrupting chemicals in human health care context: a scoping review. RMHP 2022; 15 : 779–791. doi: 10.2147/rmhp.s358561.

27. VoPham T, Bertrand KA, Jones RR et al. Dioxin exposure and breast cancer risk in a prospective cohort study. Environ Res 2020; 186 : 109516. doi: 10.1016/j.envres.2020.109516.

28. Bräuner EV, Lim YH, Koch T et al. Endocrine disrupting chemicals and risk of testicular cancer: a systematic review and meta-analysis. J Clin Endocrinol Metab 2021; 106 (12): e4834–e4860. doi: 10.1210/clinem/dgab523.

29. Ali I, Julin B, Glynn A et al. Exposure to polychlorinated biphenyls and prostate cancer: population-based prospective cohort and experimental studies. Carcinogenesis 2016; 37 (12): 1144–1151. doi: 10.1093/carcin/bgw105.

30. Cirello V, Lugaresi M, Moneta C et al. Thyroid cancer and endocrine disruptive chemicals: a case-control study on per-fluoroalkyl substances and other persistent organic pollutants. Eur Thyroid J 2024; 13 (3): e230192. doi: 10.1530/ETJ-23-0192.

31. Norouzi F, Alizadeh I, Faraji M. Human exposure to pesticides and thyroid cancer: a worldwide systematic review of the literatures. Thyroid Res 2023; 16 (1): 13. doi: 10.1186/s13044-023-00153-9.

32. Ugalde-Resano R, Gamboa-Loira B, Mérida-Ortega Á et al. Exposure to organochlorine pesticides and female breast cancer risk according to molecular receptors expression: a systematic review and meta-analysis of epidemiological evidence. Curr Environ Health Rep 2023; 10 (4): 442–458. doi: 10.1007/s40572-023-00408-5.

33. Peñalver-Piñol A, Benavente Y, Frias-Gomez J et al. Occupational exposure to pesticides and endometrial cancer in the screenwide case-control study. Environ Health 2023; 22 (1): 77. doi: 10.1186/s12940-023-01028-0.

34. Soerensen SJ, Lim DS, Montez-Rath ME et al. Pesticides and prostate cancer incidence and mortality: an environment-wide association study. Cancer 2025; 131 (1): e35572. doi: 10.1002/cncr.35572.

35. Gouesse RJ, Plante I. Environmental exposure to brominated flame retardants: unraveling endocrine and mammary gland effects that may increase disease risk. Toxicological Sciences 2022; 186 (2): 190–207. doi: 10.1093/toxsci/kfac006.

36. Hoffman K, Lorenzo A, Butt CM et al. Exposure to flame retardant chemicals and occurrence and severity of papillary thyroid cancer: a case-control study. Environ Int 2017; 107 : 235–242. doi: 10.1016/j.envint.2017.06.021.

37. Zheng J, Liu S, Yang J et al. Per -⁠ and polyfluoroalkyl substances (PFAS) and cancer: detection methodologies, epidemiological insights, potential carcinogenic mechanisms, and future perspectives. Sci Total Environ 2024; 953 : 176158. doi: 10.1016/j.scitotenv.2024.176158.

38. Cathey AL, Nguyen VK, Colacino JA et al. Exploratory profiles of phenols, parabens, and per -⁠ and poly-fluoroalkyl substances among NHANES study participants in association with previous cancer diagnoses. J Expo Sci Environ Epidemiol 2023; 33 (5): 687–698. doi: 10.1038/s41370-023-00601-6.

39. Fernández-Martínez NF, Rodríguez-Barranco M, Zamora-Ros R et al. Relationship between exposure to parabens and benzophenones and prostate cancer risk in the EPIC-Spain cohort. Environ Sci Pollut Res Int 2024; 31 (4): 6186–6199. doi: 10.1007/s11356-023-31682-3.

40. Erkekoglu P, Özyurt A, Yirün A et al. Testicular dysgenesis syndrome and phthalate exposure: a review of literature. Arhiv za farmaciju 2021; 71 (6): 508–543. doi: 10.5937/arhfarm71-34438.

41. Yang J, Luo M, Wang H et al. Phthalates unleashed: decoding ovarian carcinogenesis through multi-omics networks, single-cell insights, and molecular docking. J Ovarian Res 2025; 18 (1). doi: 10.1186/s13048-025-01710-6.

42. Sarink D, Franke AA, White KK et al. BPA, parabens, and phthalates in relation to endometrial cancer risk: a case--control study nested in the multiethnic cohort. Environ Health Perspect 2021; 129 (5): 57702. doi: 10.1289/EHP8998.